Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer before radical prostatectomy.

Freedland SJ, Carducci M, Kroeger N, Partin A, Rao JY, Jin Y, Kerkoutian S, Wu H, Li Y, Creel P, Mundy K, Gurganus R, Fedor H, King SA, Zhang Y, Heber D, Pantuck AJ.

Cancer Prev Res (Phila). 2013 Oct;6(10):1120-7. doi: 10.1158/1940-6207.CAPR-12-0423. Epub 2013 Aug 28.

PMID:
23985577
[PubMed - indexed for MEDLINE]
2.

A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.

Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, Stockton BR, Hertzman BL, Efros MD, Roper RP, Liker HR, Carducci MA.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):50-5. doi: 10.1038/pcan.2012.20. Epub 2012 Jun 12.

PMID:
22689129
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Pomegranate extract (POMx) decreases the atherogenicity of serum and of human monocyte-derived macrophages (HMDM) in simvastatin-treated hypercholesterolemic patients: a double-blinded, placebo-controlled, randomized, prospective pilot study.

Hamoud S, Hayek T, Volkova N, Attias J, Moscoviz D, Rosenblat M, Aviram M.

Atherosclerosis. 2014 Jan;232(1):204-10. doi: 10.1016/j.atherosclerosis.2013.11.037. Epub 2013 Nov 19.

PMID:
24401239
[PubMed - indexed for MEDLINE]
4.

Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention.

Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, van Breemen R, Ashton D, Bowen PE.

J Natl Cancer Inst. 2001 Dec 19;93(24):1872-9.

PMID:
11752012
[PubMed - indexed for MEDLINE]
Free Article
5.

Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.

Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A.

Clin Cancer Res. 2006 Jul 1;12(13):4018-26.

PMID:
16818701
[PubMed - indexed for MEDLINE]
Free Article
6.

Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo.

Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, Firouzi A, Rettig MB, Aronson WJ, Pantuck AJ, Heber D.

Int J Oncol. 2008 Feb;32(2):475-80.

PMID:
18202771
[PubMed - indexed for MEDLINE]
7.

Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.

Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S; Canadian Uro-Oncology Group.

J Urol. 2001 Aug;166(2):500-6; discussion 506-7.

PMID:
11458055
[PubMed - indexed for MEDLINE]
8.

Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis.

Koyama S, Cobb LJ, Mehta HH, Seeram NP, Heber D, Pantuck AJ, Cohen P.

Growth Horm IGF Res. 2010 Feb;20(1):55-62. doi: 10.1016/j.ghir.2009.09.003. Epub 2009 Oct 22.

PMID:
19853487
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.

Eastham JA, Kelly WK, Grossfeld GD, Small EJ; Cancer and Leukemia Group B.

Urology. 2003 Dec 29;62 Suppl 1:55-62.

PMID:
14747042
[PubMed - indexed for MEDLINE]
10.

Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland.

Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, Sartippour M, Harris DM, Rettig M, Suchard MA, Pantuck AJ, Belldegrun A, Heber D.

J Agric Food Chem. 2007 Sep 19;55(19):7732-7. Epub 2007 Aug 28.

PMID:
17722872
[PubMed - indexed for MEDLINE]
11.

Treatment with finasteride following radical prostatectomy for prostate cancer.

Andriole G, Lieber M, Smith J, Soloway M, Schroeder F, Kadmon D, DeKernion J, Rajfer J, Boake R, Crawford D, et al.

Urology. 1995 Mar;45(3):491-7.

PMID:
7533461
[PubMed - indexed for MEDLINE]
12.

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.

Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK.

Cancer. 2012 Oct 1;118(19):4777-84. doi: 10.1002/cncr.27416. Epub 2012 Jan 26.

PMID:
22282219
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial.

Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H, Moen A, Wessel N, Berg RE, Egge-Jacobsen W, Hammarstrom C, Svindland A, Kucuk O, Saatcioglu F, Taskèn KA, Karlsen SJ.

Nutr Cancer. 2011;63(6):889-98. doi: 10.1080/01635581.2011.582221. Epub 2011 Jun 29.

PMID:
21714686
[PubMed - indexed for MEDLINE]
14.

Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.

Marschner N, Rüttinger D, Zugmaier G, Nemere G, Lehmann J, Obrist P, Baeuerle PA, Wolf A, Schmidt M, Abrahamsson PA, Reinhardt C, Heidenreich A.

Urol Int. 2010;85(4):386-95. doi: 10.1159/000318055. Epub 2010 Jul 2.

PMID:
20606402
[PubMed - indexed for MEDLINE]
15.

Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.

Nariculam J, Freeman A, Bott S, Munson P, Cable N, Brookman-Amissah N, Williamson M, Kirby RS, Masters J, Feneley M.

Asian J Androl. 2009 Jan;11(1):109-18. doi: 10.1038/aja.2008.22. Epub 2008 Dec 1.

PMID:
19050681
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.

deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B.

Urology. 2004 Feb;63(2):259-63.

PMID:
14972467
[PubMed - indexed for MEDLINE]
17.

Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients.

Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, Dias A, Cardoza M, Laszlo S, Hersey K, Klotz L, Finelli A, Fleshner N, Vieth R.

J Clin Endocrinol Metab. 2013 Apr;98(4):1498-507. doi: 10.1210/jc.2012-4019. Epub 2013 Mar 5.

PMID:
23463655
[PubMed - indexed for MEDLINE]
18.

Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.

Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA.

Cancer. 2007 Sep 15;110(6):1248-54.

PMID:
17674353
[PubMed - indexed for MEDLINE]
Free Article
19.

Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy.

Goluboff ET, Prager D, Rukstalis D, Giantonio B, Madorsky M, Barken I, Weinstein IB, Partin AW, Olsson CA; UCLA Oncology Research Network.

J Urol. 2001 Sep;166(3):882-6.

PMID:
11490238
[PubMed - indexed for MEDLINE]
20.

Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.

Vuky J, Porter C, Isacson C, Vaughan M, Kozlowski P, Picozzi V, Corman J.

Cancer. 2009 Feb 15;115(4):784-91. doi: 10.1002/cncr.24092.

PMID:
19130458
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk